文献速递消化、代谢与肾脏急症儿科与产科急症

COVID-19大流行期间丁丙诺啡与缓释纳曲酮处方配药的种族和民族差异

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
PubMed 文献 · JAMA Netw Open · 2022-06-01
一句话结论COVID-19大流行初期,少数种族和民族群体丁丙诺啡配药量立即下降(黑人2.5%、西班牙裔4.0%),白人未下降,提示少数群体丁丙诺啡可及性损失更大。

这项横断面研究利用Symphony Health数据库2019年5月至2021年6月的零售药房索赔数据,分析1 556 860名丁丙诺啡配药者和127 506名缓释纳曲酮配药者,采用中断时间序列评估大流行前后处方配药水平与趋势。结果显示,大流行前丁丙诺啡配药率上升趋势在大流行后对所有群体均变平(趋势差异30.5个百分点,P < .001);大流行初期少数种族和民族群体丁丙诺啡配药水平显著下降(黑人2.5%,P = .009;西班牙裔4.0%,P = .009),白人未下降。按保险分层,黑人在Medicare(10.0%,P < .001)和现金支付(20.0%,P < .001)下下降幅度大于白人(Medicare 3.5%,P = .004;现金15.0%,P < .001),Medicaid患者未发现下降。缓释纳曲酮在所有群体中均出现一致的水平下降(白人私人保险10.0%至黑人Medicare 23.3%,均P < .001)和趋势下降(白人Medicaid 15.5个百分点至黑人私人保险52.0个百分点,均P < .001)。

要点

  • 大流行初期丁丙诺啡配药水平下降仅见于少数种族和民族群体:黑人2.5%(P = .009)、西班牙裔4.0%(P = .009),白人未下降。
  • 按支付方式分层,黑人丁丙诺啡配药下降幅度大于白人:Medicare黑人10.0%(P < .001)vs 白人3.5%(P = .004);现金黑人20.0%(P < .001)vs 白人15.0%(P < .001)。
  • Medicaid患者中未发现丁丙诺啡配药水平下降。
  • 缓释纳曲酮配药在所有种族和民族群体中均出现一致下降:水平下降从白人私人保险10.0%(P < .001)到黑人Medicare 23.3%(P < .001);趋势下降从白人Medicaid 15.5个百分点(P = .001)到黑人私人保险52.0个百分点(P < .001)。
  • 大流行前丁丙诺啡配药率上升趋势在大流行后对所有群体均变平,趋势差异30.5个百分点(P < .001)。

适用人群与场景

  • 2019年5月6日至2021年6月5日期间填写丁丙诺啡处方(1 556 860人)或缓释纳曲酮处方(127 506人)的个人,数据来自Symphony Health数据库,涵盖美国92%零售药房索赔,包含所有保险状态和支付方类别。
  • 丁丙诺啡配药者中亚洲人4359人(0.3%)、黑人94 657人(6.1%)、西班牙裔55 369人(3.6%)、白人664 779人(42.7%)。
  • 缓释纳曲酮配药者中亚洲人344人(0.3%)、黑人8186人(6.4%)、西班牙裔5343人(4.2%)、白人53 068人(41.6%)。

研究设计与关键结果

  • 研究设计:横断面研究,使用2019年5月至2021年6月Symphony Health零售药房索赔数据,采用中断时间序列估计大流行前后丁丙诺啡和纳曲酮配药水平与趋势。
  • 主要结局:每1000名患者每周丁丙诺啡和缓释纳曲酮配药率,以及较长(≥14天供应量)丁丙诺啡处方配药比例;分析按患者种族和民族分层,并进一步按保险状态和支付方类型对白人和黑人患者分层。
  • 大流行前丁丙诺啡配药率上升趋势在大流行后对所有群体均变平,趋势差异30.5个百分点(P < .001)。
  • 大流行初期少数种族和民族群体丁丙诺啡配药水平显著下降:黑人下降2.5%(P = .009),西班牙裔下降4.0%(P = .009);白人未下降。
  • 大流行初期,Medicare和现金支付患者的丁丙诺啡配药水平下降,黑人下降幅度大于白人:Medicare黑人10.0%(P < .001)vs 白人3.5%(P = .004);现金黑人20.0%(P < .001)vs 白人15.0%(P < .001)。
  • Medicaid患者中未发现丁丙诺啡配药水平下降。
  • 缓释纳曲酮在所有群体中均出现一致的水平下降(从白人私人保险10.0%,P < .001至黑人Medicare 23.3%,P < .001)和趋势下降(从白人Medicaid 15.5个百分点,P = .001至黑人私人保险52.0个百分点,P < .001)。

证据类型、等级与局限

  • 证据类型:横断面研究,使用零售药房索赔数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,研究结果提示少数种族和民族群体在大流行期间各类支付方下丁丙诺啡可及性损失更大。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: COVID-19 disrupted delivery of buprenorphine and naltrexone treatment for opioid use disorder (OUD), and during the pandemic, members of racial and ethnic minority groups experienced increased COVID-19 and opioid overdose risks compared with White individuals. However, whether filled buprenorphine and naltrexone prescriptions varied across racial and ethnic groups during the COVID-19 pandemic remains unknown.

OBJECTIVE: To investigate whether disruptions in filled buprenorphine and naltrexone prescriptions differed by race and ethnicity and insurance status or payer type.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used retail pharmacy claims from May 2019 to June 2021 from the Symphony Health database, which includes 92% of US retail pharmacy claims, with race and ethnicity data spanning all insurance status and payer categories. Interrupted time series were used to estimate levels and trends of dispensed buprenorphine and naltrexone prescriptions before and after pandemic onset. Included individuals were those who filled buprenorphine and extended-release naltrexone prescriptions. Data were analyzed from July 2021 through March 2022.

MAIN OUTCOMES AND MEASURES: Weekly rates of dispensed buprenorphine and extended-release naltrexone prescription fills per 1000 patients and proportion of longer (ie, ≥14 days' supply) buprenorphine prescription fills were calculated. Analyses were stratified by patient race and ethnicity and further by insurance status and payer type for White and Black patients.

RESULTS: A total of 1 556 860 individuals who filled buprenorphine prescriptions (4359 Asian [0.3%], 94 657 Black [6.1%], 55 369 Hispanic [3.6%], and 664 779 White [42.7%]) and 127 506 individuals who filled extended-release naltrexone prescriptions (344 Asian [0.3%], 8186 Black [6.4%], 5343 Hispanic [4.2%], and 53 068 White [41.6%]) from May 6, 2019, to June 5, 2021, were analyzed. Prepandemic increases in buprenorphine fill rate flattened for all groups after COVID-19 onset (30.5 percentage point difference in trend; P < .001) compared with prepandemic trends. Significant level decreases in buprenorphine fills (ranging from 2.5% for Black patients; P = .009 to 4.0% for Hispanic patients; P = .009) at pandemic onset were observed for members of racial and ethnic minority groups but not White patients. At pandemic onset, rate of buprenorphine fills decreased in level for Medicare and cash-paying patients but with greater decreases for Black patients (Medicare: 10.0%; P < .001; cash: 20.0%; P < .001) than White patients (Medicare: 3.5%; P = .004; cash: 15.0%; P < .001). No decreases were found among Medicaid patients. Unlike buprenorphine, extended-release naltrexone had uniform level (from 10.0% for White patients with private insurance; P < .001 to 23.3% for Black patients with Medicare; P < .001) and trend (from 15.5 percentage points for White patients with Medicaid; P = .001 to 52.0 percentage points for Black patients with private insurance; P < .001) decreases across groups.

CONCLUSIONS AND RELEVANCE: This study found that the COVID-19 pandemic was associated with immediate decreases in filled buprenorphine prescriptions by members of racial and ethnic minority groups but not White individuals. These findings suggest that members of racial and ethnic minority groups had larger losses in buprenorphine access during the pandemic across payer types.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Nguyen T, Ziedan E, Simon K, et al. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. JAMA Netw Open. 2022. PMID: 35648400. doi:10.1001/jamanetworkopen.2022.14765

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。